Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer

Angiogenesis

Volumn 10, Issue 3, 2007, Pages 167-182

  Ischenko, Ivan ^a   Guba, Markus ^a   Yezhelyev, Maksim ^a   Papyan, Armine ^a   Schmid, Gerald ^a   Green, Tim ^b   Fennell, Michael ^b   Jauch, Karl Walter ^a   Bruns, Christiane J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASTRAZENECA   (United Kingdom)

Author keywords

AZM475271; Orthotopic tumor model; Pancreatic cancer; Src kinase inhibition; Tumor angiogenesis

Indexed keywords

AZM 475271; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CARCINOMATOUS PERITONITIS; CELL CULTURE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; MALE; METASTASIS; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS; RATTUS;

EID: 34548158429     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-007-9071-3     Document Type: Article

References (53)

1. Folkman J (1995) Tumor angiogenesis, in the molecular basis of cancer. W.B. Saunders, Philadelphia, pp 206-232
2. Kerbel RS (2000) Tumor angiogenesis: past, present, and the near future. Carcinogenesis 21:505-515
3. Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605-619
4. Carmeliet P, Dor Y, Herbert J-M, Keshet E (1998) Role of HIV-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
5. Relf M et al (1997) Expression of the angiogenic factors in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969
6. Fukumura D et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725
7. Mukhadopathyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581
8. Jiang BH, Semenza GL (1997) V-Src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and anolase 1: involvement of HIV-1 in tumor progression. Cancer Res 57:5328-5335
9. Kerbel RS, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286-295
10. Okada F, Kerbel RS (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of VEGF/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95:3609-3614
11. Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA (1990) Association between the PDGF receptor and members of the Src family of tyrosine kinases. Cell 62:481-492
12. Arbiser JL, Folkman J (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94:861-866
13. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kallf AE, Geertzema JG, Hennipman A, Rijksen G (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180:383-388
14. Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ (1999) Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 18:1227-1237
15. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N (1987) Activation of pp60c-Src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84:2251-2255
16. Cartwright CA, Meisler AI, Eckhart W (1990) Activation of the pp60c-Src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87:558-562
17. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating Src mutation in a subset of advanced human colon cancers. Nat Genet 21:187-190
18. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, Buchler MW, Adler G (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243:503-508
19. Visser CJ, Rijksen G, Woutersen RA, de Weger RA (1996) Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-Src in preneoplastic lesions in rat pancreas. Lab Invest 74:2-11
20. Alonso G, Koegl M, Mazurenko N, Courtneidge SA (1995) Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem 270:9840-9848
21. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ (2001) Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20:1465-1475
22. Paul MK, Mukhopadhyay AK (2004) Tyrosine kinase - role and significance in cancer. Int J Med Sci 1(2):101-115
23. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J (2001) Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 276:20130-20135
24. Simeonova PP, Wang S, Hulderman T, Luster MI (2002) c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 277(4):2945-2950
25. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4:915-924
26. Sato M, Tanaka T, Maeno T, Sando Y, Suga T, Maeno Y, Sato H, Nagai R, Kurabayashi M (2002) Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway. Am J Respir Cell Mol Biol 26(1):127-134
27. Fujioka S, Yoshida K, Yanagisawa S et al (2002) Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 92:1788-1797
28. Stipa F, Lucandri G, Limiti MR et al (2002) Angiogenesis as a prognostic indicator in pancreatic ductal adenocarcinoma. Anticancer Res 22:445-449
29. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR (1999) Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis, and in pancreatic cancer. Pancreas 18:96-103
30. Baker CH, Solorzano CC, Fidler IJ (2002) Blockage of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62:1996-2003
31. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1:50-62
32. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60(11):2926-2935
33. Nicosia RF, Ottineri AA (1990) Growth of microvessels in serum-free matrix culture of rat aorta: a quantitative assay of angiogenesis in vitro. Lab Invest 63:115-122
34. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37(8):1625-1632
35. Lu Y, Yu Q, Liu JH et al (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278:40057-40066
36. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA (2000) Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19(49):5606-5613
37. Calalb MB, Polte TR, Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15(2):954-963
38. Gasparini G (1999) The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58:17-38
39. Kerbel RS (1997) A cancer therapy resistant to resistance. Nature 390:335-336
40. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856-861
41. Fontanini G, Vignati S, Bigini D, Lucchi M, Mussi A, Basolo F, Angeletti CA, Bevilacqua G (1996) Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int J Cancer 67:615-619
42. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R (1997) Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 57:1043-1046
43. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T (1997) Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 15:826-832
44. Yezhelyev M, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M, Bruns CJ (2004) Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10(23):8028-8036
45. Kleespies A, Jauch KW, Bruns CJ (2006) Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist Updat 9(1-2):1-18
46. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE (2003) Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134(2):221-226
47. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10(7):2307-2318
48. Ellis LM, Staley CA, Liu W et al (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src. J Biol Chem 273:1052-1057
49. Schlessinger J (2000) New roles for Src kinases in control of cell survival and angiogenesis. Cell 100:293-296
50. Frame M (2002) Src in cancer: deregulation and consequences for cell behavior. Biochem Biophys Acta 1062:114-130
51. Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188
52. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1:27-31
53. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85(5):683-693